BCL2 and neoplasm: Increasing miR-16 expression might be a promising strategy for tumor therapy by repressing tumor angiogenesis and inducing tumor cell death through targeting VEGF and BCL2.42, 43 miR-17 is negative regulator of angiogenesis in ECs in vitro and in vivo.